Bioanalytical Method Development For Lipids in LNP by LC-MS/MS

This event is now available on demand!

Event Overview

Understanding biodistribution is critical for evaluating the bioequivalence, bioavailability, and toxicity of a drug substance (or excipients). Residual drug substances or excipients are analyzed in various biological matrices, such as blood, plasma, serum, and tissues. The choice of matrix is mainly dependent on the route of administration. This webinar will provide some insights into:
  • Approaches taken during LC-MS/MS method development to ensure good method sensitivity
  • Optimization of sample preparation with an emphasis on protein precipitation technique
  • Ensuring method robustness before moving to validation
Key Learning Objectives
  • Learn the process of LC-MS/MS method development.
  • Learn the different sample preparation techniques used to deal with challenging biological matrices to attain target method sensitivity.
  • Learn how to ensure method robustness with a focus on method validation.
Who Should Attend
  • Analytical scientists
  • Executives in charge of CMC


Featured Speaker

Uday Velagapudi, Ph.D.
Uday Velagapudi, Ph.D.
Scientist III/Group Leader
Pace® Life Sciences

Uday Velagapudi 
is a Scientist III/Group Leader of Pharmaceutical Sciences at Pace® Life Sciences, an integrated CMC drug product development contract research organization. Uday is an SME focusing on method development for bioanalytical quantitation, small molecule and metabolite characterization, protein characterization, and host-cell protein analysis using low- and high-resolution LC-MS systems. Uday has authored or co-authored eight publications in reputable journals, such as Science and Journal of Medicinal Chemistry, and received his Ph.D. in Medicinal and Pharmaceutical Chemistry from St. John’s University in New York.

Speaker Linkedin
: https://www.linkedin.com/in/uday-kiran-velagapudi-ph-d-49b24563
Speaker email address: Uday.Velagapudi@pacelabs.com


For any technical questions please contact Jorge de la Bandera: JdelaBandera@mjhlifesciences.com